Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8779864 | 0.85 | APEX1 (0.44) | APEX1 | |
| SCHEMBL8779888 | 0.85 | APEX1 (0.44) | APEX1 | |
| SCHEMBL1430689 | 0.71 | MEN1 (0.46) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8779971 | 0.71 | MEN1 (0.46) | KMT2AMEN1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL8779876 | 0.68 | — | — | |
| SCHEMBL499416 | 0.68 | HDAC6 (0.54) | APEX1LMNAKMT2ATP53KDM4E | |
| SCHEMBL4064520 | 0.66 | APEX1 (0.55) | APEX1LMNAKMT2AMEN1KDM4E | |
| SCHEMBL8779882 | 0.66 | GGPS1 (0.43) | — | |
| SCHEMBL10475735 | 0.65 | HDAC6 (0.57) | LMNAKMT2AMEN1KDM4ESMN1; SMN2 | |
| SCHEMBL5869878 | 0.64 | POLB (0.53) | LMNAKMT2AMEN1TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-06-12 | — | — | US | disclosed |
| US-8673909-B2 | Indole compounds and methods for treating visceral pain | NEURAXON, INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8618286-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-12-31 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2012-05-17 | — | — | US | disclosed |
| US-8106043-B2 | Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2012-01-31 | — | — | US | disclosed |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2011-09-01 | — | — | US | disclosed |
| US-7989447-B2 | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2011-08-02 | — | — | US | disclosed |
| US-7951940-B2 | neuronal nitric oxide synthase (nNOS) isoform inhibitors; 2-ethyl-1-(1H-indol-5-yl)-isothiourea; neurogenerative disorders, stroke, reperfusion injury, head trauma, migraine headache, neuropathic pain, drug abuse, hyperalgesia | NEURAXON, INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| WO-2010000073-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2010-01-07 | — | — | WO | disclosed |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | NEURAXON, INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | NEURAXON, INC (CA) | 2009-05-21 | — | — | US | disclosed |
| EP-2010527-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | Neuraxon Inc. (CA) | 2009-01-07 | — | — | EP | disclosed |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON INC. (CA) | 2008-10-09 | — | — | US | disclosed |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2008-09-25 | — | — | US | disclosed |
| US-7375219-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2008-05-20 | — | — | US | disclosed |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2007-11-01 | — | — | US | disclosed |
| WO-2007118314-A1 | 1,5 AND 3,6- SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2007-10-25 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131503-A1 | 3,5 - SUBSTITUTED INDOLE COMPOUNDS HAVING NOS AND NOREPINEPHRINE REUPTAKE INHIBITORY ACTIVITY | SLC6A2, AANAT, NOS3 | APEX1 2457/4885LMNA 3275/4885KMT2A 3105/4885 |
| US-20110212947-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | APEX1 3410/4885LMNA 3365/4885KMT2A 2332/4885 |
| US-20120122855-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | APEX1 2462/4885LMNA 3142/4885KMT2A 2758/4885 |
| US-20080249302-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | APEX1 3410/4885LMNA 3365/4885KMT2A 2332/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | APEX1 3410/4885LMNA 3365/4885KMT2A 2332/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | APEX1 3410/4885LMNA 3365/4885KMT2A 2332/4885 |
| US-20080234237-A1 | QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS1, NOS2, NOS3 | APEX1 1184/4885LMNA 2991/4885KMT2A 2245/4885 |
| US-20070254940-A1 | 1,5 And 3,6- substituted indole compounds having NOS inhibitory activity | NOS1, NOS3, NOS2 | APEX1 2904/4885LMNA 2469/4885KMT2A 3297/4885 |
| US-20090192157-A1 | INDOLE COMPOUNDS AND METHODS FOR TREATING VISCERAL PAIN | TPH1, NOS1, IDO1 | APEX1 2038/4885LMNA 3941/4885KMT2A 2112/4885 |
| US-20140163016-A1 | BENZOXAZINES, BENZOTHIAZINES, AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | APEX1 2462/4885LMNA 3142/4885KMT2A 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.